Conditions: Alzheimer's Disease
Keywords: Agitation Aggression AD patients
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 296
Healthy volunteers: no

Brief summary:
To evaluate the safety and tolerability of ELND005 treatment with up to 36 weeks exposure, in Moderate to Severe AD patients with agitation and aggression.

Detailed description:

Arms:
arm 1: Patients who received ELND005 during Study AG201 will continue on the same maintenance dose for 36 weeks. arm 2: Patients who received placebo during Study AG201 will receive ELND005 at the same dosing regimen as the active group in Study AG201 for 36 weeks.

Interventions: intervention 1: Group 1 ELND005 intervention 2: Group 2 ELND005
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: